Evaluating the risk-benefit profile of the direct-acting P2Y 12 inhibitor ticagrelor in acute coronary syndromes

Postgraduate Medicine

Volumn 123, Issue 6, 2011, Pages 79-90

  Husted, Steen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute coronary syndromes; Clopidogrel; Plato; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; KETOCONAZOLE; MEVINOLIN; PRASUGREL; RIFAMPICIN; SIMVASTATIN; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL PRACTICE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADENOSINE; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; GENOTYPE; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TICLOPIDINE;

EID: 82255169699     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.11.2498     Document Type: Article

References (55)

1. World Health Organization. World Health Organization Fact Sheet No. 310: The top ten causes of death. http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed August 23, 2011.
2. Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-e304.
3. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [published online ahead of print September 21, 2011]. Eur Heart J.
4. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205-2241.
5. Van de Werf F, Bax J, Betriu A, et al; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909-2945.
6. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038-1047.
7. Husted S. Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundam Clin Pharmacol. 2009;23(1):1-9.
8. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24(11): 1980-1987.
9. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107(23):2908-2913.
10. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin Proc. 2006;81(4):518-526.
11. Van de Werf F. Dual antiplatelet therapy in high-risk patients. Eur Heart J Suppl. 2007;9:D3-D9.
12. Shuldiner AR, O'Connell JR, Bliden, KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-858.
13. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27(20):2420-2425.
14. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol. 2005;45(8):1157-1164.
15. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16):1964-1977.
16. CURRENT-OASIS 7 Investigators; Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930-942.
17. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standarddose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-1243.
18. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66.e9-66.e16.
19. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166-1173.
20. Wiviott SD, Antman EM, Winters KJ, et al; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111(25):3366-3373.
21. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
22. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med. 2007;357(20):2078-2081.
23. US Food and Drug Administration. FDA Drug Safety Communication. 2009 Medication Guide. Effient™ (prasugrel). http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022307s000MEDGU IDE.pdf. Accessed August 23, 2011.
24. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259-274.
25. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577-2585.
26. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy infjects. Drug Metab Dispos. 2010;38(9):1514-1521.
27. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50(19):1844-1851.
28. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET infstudy. J Am Coll Cardiol. 2010;56(18):1456-1462.
29. Husted SE, Gurbel P, Storey RF, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease. Circulation. 2009;120:S1102 (Abstract 5494).
30. James S, Åkerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157(4):599-605.
31. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-1057.
32. King SB 3rd, Smith SC Jr, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO; 2005 Writing Committee Members, et al. Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117(2):261-295.
33. Stenestrand U, Johansson S, Janzon M, Wallentin L. The platelet inhibition and patient outcomes trial (PLATO) is representative of patients with acute coronary syndromes in a National Heart Registry. J Am Coll Cardiol. 2010;55:A112 Abstract E1046.
34. Scirica BM, Cannon CP, Emanuelsson H. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment infstudy. J Am Coll Cardiol. 2011;57(19):1908-1916.
35. Wallentin L, for the PLATO investigators. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial. Presented at: European Society of Cardiology; August 30, 2009; Barcelona, Spain. http://www.escardio.org/congresses/esc-2009/congress-reports/Pages/70600 5-706006-wallentin-kristensen.aspx#discussant. Accessed August 23, 2011.
36. Cannon CP, Harrington RA, James S, et al; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283-293.
37. James S, Roe M, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management - a infstudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527.
38. Steg G, James S, Harrington RA, et al; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary PCI: a Platelet Inhibition and Patient Outcomes (PLATO) trial infgroup analysis. Circulation. 2010;122(21):2131-2141.
39. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a infstudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006-3016.
40. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery by-pass surgery: results from the PLATO trial. J Am Coll Cardiol. 2011;57(6):672-684.
41. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544-554.
42. Brilinta [package insert]. Wilmington, DE: AstraZeneca. July 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022433s000lbl.p df. Accessed September 27.
43. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852-1856.
44. Rao SV, O'Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47(4): 809-816.
45. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes [published online ahead of print July 30, 2011]. Eur Heart J.
46. Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185-193
47. Storey RF, Becker RC, Harrington RA, et al. Pulmonary Function in Patients with Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Infstudy) [published online ahead of print September 3, 2011]. Am J Cardiol.
48. AstraZeneca. AstraZeneca FDA Advisory Committee Briefing Document. June 23, 2010. Ticagrelor Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting NDA 22-433. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria ls/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM220197.pdf. Accessed August 23, 2011.
49. James SK, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-1067.
50. Husted S. Evidence-based prescribing and adherence to antiplatelet therapy-how much difference do they make to patients with atherothrombosis? Int J Cardiol. 2009;134(2):150-159.
51. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic infstudy of the PLATO trial. Lancet. 2010;376(9749):1320-1328.
52. Gurbel P, Bliden K, Antonino M, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188-1199.
53. Gurbel PA, Mahla E, Antonino MJ, Tantry US. Response variability and the role of platelet function testing. J Invasive Cardiol. 2009;21(4):172-178.
54. Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J. 2011; 162(1):160-165.
55. Janzon M, Nikolic E, Henriksson M, et al. Health economics in the PLATelet inhibition and patient Outcomes (PLATO) randomized trial: report on within trial resource use patterns. Circulation 2010; 122: (Abstract 17295). Poster presentation at: American Heart Association 2010 Scientific Sessions; Chicago, IL; November 13-17, 2010.